Tevogen Bio (NASDAQ:TVGN) Posts Quarterly Earnings Results, Beats Expectations By $1.01 EPS

Tevogen Bio (NASDAQ:TVGN) released its quarterly earnings data on Friday. The company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.53) by $1.01, FiscalAI reports.

Tevogen Bio Stock Performance

NASDAQ TVGN traded up $0.30 on Friday, reaching $6.87. The company’s stock had a trading volume of 8,215 shares, compared to its average volume of 25,368. The stock has a market cap of $28.99 million, a PE ratio of -1.49 and a beta of 0.18. Tevogen Bio has a twelve month low of $3.64 and a twelve month high of $49.50. The firm’s 50 day moving average is $7.02 and its two-hundred day moving average is $8.34.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a report on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $100.00.

Hedge Funds Weigh In On Tevogen Bio

Hedge funds have recently modified their holdings of the stock. Deutsche Bank AG boosted its position in shares of Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares during the period. Goldman Sachs Group Inc. lifted its stake in Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after acquiring an additional 152,572 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in shares of Tevogen Bio by 66.7% in the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after purchasing an additional 33,000 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.